This AI-generated translation is currently being refined.
DOLOSPASMYL contains two active ingredients: - Alverine, which belongs to a class of medications called musculotropic antispasmodics, - And simethicone, which belongs to a class of medications called antiflatulents. This medication reduces intestinal muscle contractions and bloating (gas). It is used to relieve pain associated with intestinal contractions (spasms) accompanied by bloating. This medication is intended for adults only.
Medicine
DoloSpasmyl, Pain associated with intestinal cramps accompanied by bloating, box of 10 soft capsules
1 box of 10 soft gel capsules
3,95€
In stockThis is a medicine. Information on precautions for use (drug interactions, contraindications, special warnings, adverse reactions...) and dosage are detailed in the summary of product characteristics.
In accordance with current regulations, any suspected adverse effect of a medication must be reported: Een bijwerking melden. .
Read the package insert carefully before use.
FOR ADULTS ONLY
1 capsule 2 to 3 times a day at the start of meals or when pain occurs.
Treatment should not exceed 10 days without a doctor's advice.
Pregnancy:
Simethicone: No effects are expected during pregnancy when taking simethicone due to negligible systemic exposure.
Alverine: There are no comprehensive teratogenicity data from animal studies. Clinically, no specific teratogenic or fetotoxic effects have been observed to date. However, follow-up of pregnancies exposed to alverine is insufficient to rule out any risk.
Consequently, as a precautionary measure, it is preferable not to use DOLOSPASMYL during pregnancy.
Breastfeeding:
No effects from simethicone taken during breastfeeding are expected due to negligible systemic exposure.
There are no data on the transfer of alverine into breast milk.
Consequently, the use of DOLOSPASMYL should be avoided while breastfeeding.
FOR ADULTS ONLY
1 capsule 2 to 3 times a day at the start of meals or when pain occurs.
Treatment should not exceed 10 days without a doctor's advice.
Pregnancy:
Simethicone: No effects are expected during pregnancy when taking simethicone due to negligible systemic exposure.
Alverine: There are no comprehensive teratogenicity data from animal studies. Clinically, no specific teratogenic or fetotoxic effects have been observed to date. However, follow-up of pregnancies exposed to alverine is insufficient to rule out any risk.
Consequently, as a precautionary measure, it is preferable not to use DOLOSPASMYL during pregnancy.
Breastfeeding:
No effects from simethicone taken during breastfeeding are expected due to negligible systemic exposure.
There are no data on the transfer of alverine into breast milk.
Consequently, the use of DOLOSPASMYL should be avoided while breastfeeding.
Citrate d'alvérine 60,00 mg/Siméticone 300,00 mg, pour une capsule molle.
Pour la liste complète des excipients, voir la notice.
Pour la liste complète des excipients, voir la notice.
Log in 
